| scholarly article | Q13442814 |
| P356 | DOI | 10.1056/NEJMOA1003812 |
| P698 | PubMed publication ID | 21675889 |
| P50 | author | Ray Borrow | Q64500634 |
| Richard Adebayo Adegbola | Q75114791 | ||
| Samba Sow | Q87002144 | ||
| Brian D. Plikaytis | Q106893185 | ||
| George M Carlone | Q106918891 | ||
| Helen Findlow | Q114779771 | ||
| P2093 | author name string | Prasad S Kulkarni | |
| Aldiouma Diallo | |||
| Simonetta Viviani | |||
| Brown J Okoko | |||
| Adebayo K Akinsola | |||
| F Marc LaForce | |||
| Yuxiao Tang | |||
| Elisa Marchetti | |||
| Olubukola T Idoko | |||
| Doudou Diop | |||
| Fatoumata Diallo | |||
| Varsha Parulekar | |||
| Marie-Pierre Preziosi | |||
| Fadima Cheick Haidara | |||
| Cheryl Elie | |||
| Julie Chaumont | |||
| Lionel Martellet | |||
| Milagritos Tapia | |||
| Pascal Arduin | |||
| P433 | issue | 24 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | vaccine | Q134808 |
| P304 | page(s) | 2293-2304 | |
| P577 | publication date | 2011-06-01 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. | |
| P478 | volume | 364 |
| Q36265095 | A Phase 3, Double-Blind, Randomized, Active Controlled Study to Evaluate the Safety of MenAfriVac in Healthy Malians |
| Q35922578 | A Seroepidemiological Study of Serogroup A Meningococcal Infection in the African Meningitis Belt |
| Q34808847 | A field based evaluation of adverse events following MenAfriVac® vaccine delivered in a controlled temperature chain (CTC) approach in Benin |
| Q36849830 | A randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in children aged 2-10 years |
| Q92441313 | A review of complement sources used in serum bactericidal assays for evaluating immune responses to meningococcal ACWY conjugate vaccines |
| Q39032700 | A vaccine to prevent epidemic meningitis in Africa |
| Q43928763 | A vaccine to prevent epidemic meningitis in Africa |
| Q36265001 | Active Surveillance for Adverse Events After a Mass Vaccination Campaign With a Group A Meningococcal Conjugate Vaccine (PsA-TT) in Mali |
| Q38040527 | Advances with vaccination against Neisseria meningitidis |
| Q37974423 | Adverse events following immunization during mass vaccination campaigns at first introduction of a meningococcal A conjugate vaccine in Burkina Faso, 2010. |
| Q30391463 | After 2015: infectious diseases in a new era of health and development |
| Q28598111 | Ambiguous Capture: Collaborative Capitalism and the Meningitis Vaccine Project |
| Q33850814 | An epidemiological review of changes in meningococcal biology during the last 100 years |
| Q46265378 | An outer membrane vesicle vaccine for prevention of serogroup A and W-135 meningococcal disease in the African meningitis belt |
| Q38099177 | An overview of meningococcal disease in India: knowledge gaps and potential solutions |
| Q64361873 | Antibodies against Haemophilus influenzae type b in The Gambia: investigating the extent of protection across age groups |
| Q36265103 | Antibody Persistence 1-5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12-23 Months of Age. |
| Q36265032 | Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2-29 Years |
| Q91466956 | Antibody kinetics following vaccination with MenAfriVac: an analysis of serological data from randomised trials |
| Q48505883 | Assessing the Importance of Domestic Vaccine Manufacturing Centers: An Overview of Immunization Programs, Vaccine Manufacture, and Distribution. |
| Q38011318 | Can we defeat meningococcal disease in low and middle income countries? |
| Q38011316 | Can we, should we, eradicate the meningococcus? |
| Q38416020 | Capacity for a global vaccine safety system: the perspective of national regulatory authorities. |
| Q26778263 | Challenges and Opportunities While Developing a Group A Meningococcal Conjugate Vaccine Within a Product Development Partnership: A Manufacturer's Perspective From the Serum Institute of India |
| Q34353041 | Characterization of size, structure and purity of serogroup X Neisseria meningitidis polysaccharide, and development of an assay for quantification of human antibodies |
| Q56890266 | Clinical data supporting a 2-dose schedule of MenB-FHbp, a bivalent meningococcal serogroup B vaccine, in adolescents and young adults |
| Q26778276 | Community Perspectives Associated With the African PsA-TT (MenAfriVac) Vaccine Trials |
| Q39214102 | Conducting vaccine clinical trials in sub-Saharan Africa: operational challenges and lessons learned from the Meningitis Vaccine Project |
| Q42287903 | Conjugate vaccine introduction in the African meningitis belt: meeting surveillance objectives |
| Q42281822 | Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa? |
| Q38004749 | Critical episodes in the understanding and control of epidemic meningococcal meningitis |
| Q33601899 | Development and use of a serum bactericidal assay using pooled human complement to assess responses to a meningococcal group A conjugate vaccine in African toddlers |
| Q34267478 | Development of a group A meningococcal conjugate vaccine, MenAfriVac(TM). |
| Q46758477 | Developmental strategy fora new Group A meningococcal conjugate vaccine (MenAfriVacR). |
| Q36103475 | Distribution of Bexsero® Antigen Sequence Types (BASTs) in invasive meningococcal disease isolates: Implications for immunisation |
| Q30566557 | Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study [corrected]. |
| Q38058959 | Effect of vaccines on bacterial meningitis worldwide |
| Q30239049 | Emergence and control of epidemic meningococcal meningitis in sub-Saharan Africa |
| Q37956384 | Epidemiology and prevention of meningococcal disease: a critical appraisal of vaccine policies |
| Q92890378 | Evaluation of the adverse events following immunization surveillance system in Guruve district, Mashonaland Central 2017 |
| Q38286082 | Evolving meningococcal immunization strategies |
| Q38829564 | Fighting Neisseria meningitidis: past and current vaccination strategies |
| Q38011321 | Future challenges in the elimination of bacterial meningitis |
| Q38044755 | Glycoconjugate vaccines. |
| Q38286346 | Glycoconjugate vaccines: an update. |
| Q38011311 | History of meningococcal vaccines and their serological correlates of protection |
| Q38944335 | Human Complement Bactericidal Responses to a Group A Meningococcal Conjugate Vaccine in Africans and Comparison to Responses Measured by 2 Other Group A Immunoassays |
| Q34721179 | Identifying optimal vaccination strategies for serogroup A Neisseria meningitidis conjugate vaccine in the African meningitis belt |
| Q50919180 | Immunogenicity and safety of a new meningococcal A conjugate vaccine in Indian children aged 2-10 years: a phase II/III double-blind randomized controlled trial. |
| Q36781534 | Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2-10-year-old children: results of an open, randomised, controlled study |
| Q40045360 | Impact of Controlled Temperature Chain (CTC) approach on immunization coverage achieved during the preventive vaccination campaign against meningitis A using MenAfriVac in Togo in 2014 |
| Q27012771 | Impact, challenges, and future projections of vaccine trials in Africa |
| Q38867783 | Incidence and types of adverse events during mass vaccination campaign with the meningococcal a conjugate vaccine (MENAFRIVAC™) in Cameroon. |
| Q38177632 | Indian Academy of Pediatrics (IAP) recommended immunization schedule for children aged 0 through 18 years, India, 2013 and updates on immunization |
| Q36265075 | Influence of Age on Antibody Response and Persistence Following Immunization With MenAfriVac |
| Q26778267 | Introduction and Rollout of a New Group A Meningococcal Conjugate Vaccine (PsA-TT) in African Meningitis Belt Countries, 2010-2014 |
| Q46027898 | Investigating the immunodominance of carbohydrate antigens in a bivalent unimolecular glycoconjugate vaccine against serogroup A and C meningococcal disease. |
| Q38952780 | Investigation of correlates of protection against pharyngeal carriage of Neisseria meningitidis genogroups W and Y in the African meningitis belt |
| Q36265065 | Lessons Learned From Enhancing Vaccine Pharmacovigilance Activities During PsA-TT Introduction in African Countries, 2010-2013. |
| Q41488993 | Low immunogenicity of quadrivalent meningococcal vaccines in solid organ transplant recipients |
| Q36265023 | MenAfriVac as an Antitetanus Vaccine |
| Q36265037 | Meningococcal Seroepidemiology 1 Year After the PsA-TT Mass Immunization Campaign in Burkina Faso |
| Q37632051 | Meningococcal carriage in the African meningitis belt |
| Q35198778 | Meningococcal factor H binding proteins in epidemic strains from Africa: implications for vaccine development |
| Q38282047 | Meningococcal group C and w135 immunological hyporesponsiveness in african toddlers |
| Q27028161 | Meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine: a new conjugate vaccine against invasive meningococcal disease |
| Q34210674 | Meningococcal vaccine introduction in Mali through mass campaigns and its impact on the health system. |
| Q102323243 | Meningococcal vaccines and protein-energy undernutrition in children in the African meningitis belt |
| Q58705762 | Meningococcus serogroup C clonal complex ST-10217 outbreak in Zamfara State, Northern Nigeria |
| Q38936876 | Monitoring adverse events following immunization with a new conjugate vaccine against group A meningococcus in Niger, September 2010. |
| Q34785389 | Mutant Native Outer Membrane Vesicles Combined with a Serogroup A Polysaccharide Conjugate Vaccine for Prevention of Meningococcal Epidemics in Africa |
| Q36265012 | Neisseria meningitidis Group A IgG1 and IgG2 Subclass Immune Response in African Children Aged 12-23 Months Following Meningococcal Vaccination |
| Q34707962 | Persistent low carriage of serogroup A Neisseria meningitidis two years after mass vaccination with the meningococcal conjugate vaccine, MenAfriVac |
| Q34892719 | Phenotypic and genotypic characterization of meningococcal carriage and disease isolates in Burkina Faso after mass vaccination with a serogroup a conjugate vaccine |
| Q36265080 | Population-Level Persistence of Immunity 2 Years After the PsA-TT Mass-Vaccination Campaign in Mali |
| Q42244474 | Preclinical immunogenicity and functional activity studies of an A+W meningococcal outer membrane vesicle (OMV) vaccine and comparisons with existing meningococcal conjugate- and polysaccharide vaccines |
| Q26998634 | Priorities for research on meningococcal disease and the impact of serogroup A vaccination in the African meningitis belt |
| Q28679578 | Profile: the Niakhar Health and Demographic Surveillance System |
| Q24186676 | Rapid diagnostic tests for bacterial meningitis applicable in sub-Saharan Africa |
| Q45044609 | Relative stability of meningococcal serogroup A and X polysaccharides |
| Q35897046 | Response Strategies against Meningitis Epidemics after Elimination of Serogroup A Meningococci, Niger |
| Q28828692 | Review of meningococcal vaccines with updates on immunization in adults |
| Q37014766 | Rise of the microbes |
| Q36265100 | Risk Assessment and Meningococcal A Conjugate Vaccine Introduction in Africa: The District Prioritization Tool |
| Q26778259 | Safety Monitoring in Group A Meningococcal Conjugate Vaccine Trials: Description, Challenges, and Lessons |
| Q41589390 | Safety and immunogenicity of a meningococcal quadrivalent conjugate vaccine in five- to eight-year-old Saudi Arabian children previously vaccinated with two doses of a meningococcal quadrivalent polysaccharide vaccine |
| Q37992392 | Safety reporting in developing country vaccine clinical trials-a systematic review |
| Q34346578 | Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data |
| Q38584375 | Serogroup A meningococcal conjugate vaccines in Africa |
| Q36212055 | Serogroup W Meningitis Outbreak at the Subdistrict Level, Burkina Faso, 2012. |
| Q34606343 | Seroprevalence of bactericidal, specific IgG antibodies and incidence of meningitis due to group A Neisseria meningitidis by age in Burkina Faso 2008 |
| Q47920054 | Successful African introduction of a new Group A meningococcal conjugate vaccine: Future challenges and next steps |
| Q41669855 | Synthesis and immunological evaluation of protein conjugates of Neisseria meningitidis X capsular polysaccharide fragments |
| Q61448107 | The Impact of Nucleotide Sequence Analysis on Meningococcal Vaccine Development and Assessment |
| Q37969481 | The changing and dynamic epidemiology of meningococcal disease |
| Q42577186 | The endgame for serogroup a meningococcal disease in Africa? |
| Q36391883 | The immunogenicity and safety of an investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) compared with a licensed meningococcal tetravalent polysaccharide vaccine: a randomized, controlled non-inferiorit |
| Q39186214 | The impact of pre-existing antibody on subsequent immune responses to meningococcal A-containing vaccines |
| Q37037419 | The impact of protein-conjugate polysaccharide vaccines: an endgame for meningitis? |
| Q53669745 | Under-reporting of venous and arterial thrombotic events in randomized clinical trials: a meta-analysis. |
| Q46535546 | Vaccine Prevention of Meningococcal Disease in Africa: Major Advances, Remaining Challenges |
| Q37514748 | Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future |
| Q34119892 | Vaccines against poverty |
| Q26824128 | Vaccines for low-income countries |
| Q51664205 | Vaccines for the twenty-first century society. |
| Q38882884 | Vaccines safety; effect of supervision or SMS on reporting rates of adverse events following immunization (AEFI) with meningitis vaccine (MenAfriVac™): a randomized controlled trial |
| Q34140152 | Whom and where are we not vaccinating? Coverage after the introduction of a new conjugate vaccine against group A meningococcus in Niger in 2010 |
| Q54108348 | [Anti-meningococcal vaccines: diversity of vaccination policies and recommendations]. |
Search more.